CFO4Life’s AbbVie ABBV Stock Holding History

CFO4Life’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$713K	Buy	+4,415	New	+$677K	0.15%	76
2016 Q4	–	Sell	-8,209	Closed	-$518K	–	92
2016 Q3	$518K	Buy	+8,209	New	+$531K	0.45%	36

Other funds holding ABBV

AWA

Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

CFO4Life's ABBV Position: Q4 2022 in Review

CFO4Life opened a new position in AbbVie (ABBV) in Q4 2022: 4,415 shares worth $713K. The stake represents 0.15% of the portfolio and ranks #76 among its holdings. This is a return to the name: CFO4Life previously reported a position in ABBV as recently as Q3 2016.

CFO4Life first reported a position in ABBV in Q3 2016 and has held it in 2 quarters since. 3,170 funds tracked by Wall St. Rank hold ABBV as of Q4 2022.

CFO4Life held 4,415 shares of AbbVie worth $713K as of Q4 2022.
AbbVie was a new CFO4Life position in Q4 2022.
AbbVie made up 0.15% of CFO4Life's portfolio in Q4 2022, its #76 holding.
CFO4Life first reported a position in AbbVie in Q3 2016 and has held it in 2 quarters since.
3,170 funds tracked by Wall St. Rank held AbbVie as of Q4 2022.

Based on CFO4Life's 13F filing for Q4 2022, filed 11 Jan 2023.